MANCHESTER, U.K.—Synexus, a company focused on recruitinglarge volumes of high-quality patients for clinical trials run at its owndedicated research centers on behalf of pharmas, biotechs and contract researchorganizations (CROs), has been operating in Poland since 2006. It expanded thatreach in August 2009 when it acquired three new dedicated research centers inWarsaw, Gdynia and Katowice—then expanded its centers in Gdynia and Wroclaw thefollowing year—and in early May of this year, it took a step to furtherstrengthen its position in Poland with the acquisition of Medical CentreOsteomed for an undisclosed sum.
Based in Warsaw, Osteomed is described by Synexus as "awell-established and highly respected clinical research company, FDA audited,whose client list includes many of the world's leading pharmaceutical companiesand CROs." In conjunction with the announcement, Dr. Christophe Berthoux, CEOof Synexus, reports that his company will consolidate its presence in Warsawinto a new research clinic that is four times the size of Synexus' currentWarsaw facility. Moreover, in the past two years, Synexus will have quadrupledits capacity across its four sites in Wroclaw, Gdynia, Warsaw and Katowice, henotes.
As for the question of why there has been so much expansion,Berthoux points to the fact that Poland has become a significant player in theglobal clinical trials market and notes that analysts predict that market willgrow to reach $323 million by 2015. According to Synexus, the country offersmany benefits, such as access to high-quality medical expertise, significantcost advantages, a motivated patient population and excellent trial dataquality.
"Synexus has long recognized the importance of Poland in theglobal clinical trials market in terms of the significant opportunities thisregion can offer," Berthoux noted in the news release about the acquisition."We have had a well-established presence in Poland for a number of years, butfelt that now was the time to further strengthen this, both in recognition ofthe area as well as in support of our business growth. The acquisition ofOsteomed will enhance our capacity, brings us scientific expertise andexperience in the field of bone diseases and access to an extensive patientdatabase."
It also creates what he calls "a third pillar" in thecompany's global infrastructure, with the other two pillars being the UnitedKingdom and Germany.
"Synexus' success in Poland will be used as a platform togrow our business across Central and Eastern Europe, where we already haveclinics in Hungary, Ukraine and Bulgaria," he continued. "This infrastructureenables us to offer scale and capacity to clients as well as stability, whichare seen as vital by the pharmaceutical industry."
Dr. Andrzej Sawicki and Piotr Sawicki, who had ownedOsteomed, will remain with Synexus. According to Synexus, Andrzej Sawickienhances the senior medical team because of his status as a recognized expertin clinical research in bone diseases. Piotr Sawicki is being appointed to asenior position within Synexus Poland.
"Since I founded Osteomed 18 years ago, we have developed asolid reputation, which is a measure of our knowledge and experience as well asthe high quality of our work, said Andrzej Sawicki in an official statement."Synexus has a high regard for quality and professionalism and, therefore, weare very pleased to be working with them."
Medical Centre Osteomed has been involved in clinical trialsfrom Phase I through Phase IIIb and although it was founded with the goal ofconducting studies in field of osteoporosis, its website notes that it iscurrently capable of conducting studies in a wide range of other therapeuticareas as well, ranging from diabetes to dementia, cardiology to oncology, sleepdisorders to seizure disorders, and more.